uploads///laboratory _

What Do Analysts Recommend for Pfizer ahead of Its Q4 Results?

By

Jan. 22 2019, Published 8:02 a.m. ET

Analysts’ recommendations

Pfizer (PFE) is expected to post its earnings results for the fourth quarter of 2018 on January 29, 2019.

Before we discuss the company’s fourth-quarter estimates, let’s take a look at its share price performance as well as analysts’ recommendations ahead of its impending earnings release. These factors are indicative of investors’ and analysts’ sentiments about the company.

Of the 14 analysts covering Pfizer on January 19, one has rated it as a “strong buy,” five have rated it as a “buy,” seven analysts have rated it as a “hold,” and one has rated it as a “strong sell.”

Article continues below advertisement

The 12-month consensus analyst recommendation for Pfizer as of January 19 is a “hold.” The 12-month consensus target price for the company is $45.35, which is 6.63% higher than its closing price on January 18. The highest, median, and lowest target price estimates for the company are $54, $46, and $36, respectively.

Share price movements

On January 18, Pfizer closed at $42.53, 0.14% higher than its previous day’s closing price. The company closed at a premium of 28.10% to its 52-week low of $33.20 and at a discount of 8.48% to its 52-week high of $46.47. As of the end of January 18, Pfizer’s market cap was $249.86 billion. The company is trading at a trailing PE ratio of 17.74x and a forward PE ratio of 13.83x.

Based on its closing price on January 18, Pfizer had reported returns of -0.82% in the last week, 0.31% in the last month, and -4.58% in the last quarter. Pfizer had also reported returns of 13.84% in the last half year, 14.98% in the last year, and -2.57% YTD (year-to-date).

Based on its closing price on January 18, the broader market represented by the SPDR S&P 500 ETF (SPY) had reported returns of 2.89% in the last week, 4.46% in the last month, and -4.99% in the last quarter. SPY had also reported returns of -4.84% in the last half year, -4.54% in the last year, and 6.62% YTD.

Pfizer has underperformed SPY in 2019 YTD, but it mostly outperformed the ETF in 2018.

In the next article, we’ll discuss Pfizer’s EPS estimates for the fourth quarter and 2018 in greater detail.

Advertisement

More From Market Realist